This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Prostate Cancer. Measurement will happen over the course of 1 year.
This trial requires 240 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
"Prostate cancer is a type of cancer that forms in the prostate gland and typically appears in men over the age of 50. The clinical features of prostate cancer vary widely and can lead to variable responses to treatment.\n" - Anonymous Online Contributor
"Men diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) often receive radiation and/or hormonal therapy, and men who do not receive treatment for prostate cancer develop a cancer in another area of the body. When prostate cancer is detected early, treatment can be effective, although the treatment is more likely to fail if the cancer has spread beyond the prostate." - Anonymous Online Contributor
"About 11.7 million men are diagnosed with prostate cancer a year in the United States, the majority of which are less than 76 years of age at diagnosis. This makes up 19.3% of US men." - Anonymous Online Contributor
"Signs of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) include persistent or worsening leg swelling, pain with standing, unexplained blood in the urine, or unexplained loss of weight. In men with symptoms of prostatic enlargement or a palpable abnormal prostate gland, further evaluation with laboratory tests or urology or imaging is recommended to find signs and clues for prostate cancer.\n" - Anonymous Online Contributor
"Though radical prophylactic radiotherapy, including brachytherapy, has been proven to be effective in controlling localized stage 1-3B prostate cancer, there is a paucity of data detailing the efficacy of adjuvant brachytherapy in local control of this disease entity. Results from a recent clinical trial shows that the addition of brachytherapy to radical hysterectomy may indeed be highly effective, even in recurrent advanced disease." - Anonymous Online Contributor
"The main causes of prostate cancer are age and genetics. The risks are greater in men over the age of 50 years. Chemotherapy and hormonal therapy have been used to treat prostate cancer." - Anonymous Online Contributor
"The number of men in Russia undergoing RP increased during these time periods. More than 1 million PAs were administered annually, which resulted in an estimated 250,000 deaths from [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in Russia. The number of PAs increased from 40 per 1000 procedures in 1988, to 100 per 1000 procedures in 1998, and to 147 per 1000 procedures in 2001. The rate of cancer detection, however, did not increase. It therefore appears that increased PAs in Russia were not in part responsible for the increase in PAs. The primary cause may have been decreased PAs for localized prostate cancer, which accounted for nearly 60% of PAs in 1999 and 2000, compared with 48% in 1988 and 1989." - Anonymous Online Contributor
"Treatment with androgen deprivation therapies is associated with sexual side effects. The effects on sexual function are usually mild. Older men are at higher risk of developing sexual dysfunction. A common side effect, with clinical relevance, is sexual dysfunction. The use of testosterone does not appear to increase the risk of prostate cancer." - Anonymous Online Contributor
"We conclude that the two-year adjuvant therapy with E1(102)Lu-DOTATATE and cetuximab was safe and more effective for the treatment of relapsed metastatic prostate cancer with PSA >or=20 ng/ml than either a placebo or a standard cytotoxic treatment with doxorubicin or docetaxel. The therapeutic benefit of E1(102)Lu-DOTATATE was accompanied by minimal side effects and no treatment-related deaths." - Anonymous Online Contributor
"Prostate cancer patients have a good prognosis for treatment. The risk of death or relapse is low. The risk of progression is decreased if the patient is followed up and treated early. This treatment, surgery, and radiation treatment can be done before there are significant symptoms of cancer or at the time of a tumor is still small." - Anonymous Online Contributor
"Current research on prostate cancer is primarily centered around hormonal therapies, which include selective estrogen-receptor modulators (SERMs), androgen-receptor antagonists, androgen-deprivation therapy (ADT), and inhibitors; however, there are also ongoing studies on the use of chemotherapeutic agents." - Anonymous Online Contributor
"As is often in practice, men were treated first for their disease, not for their symptoms. Symptom control was accomplished by use of drugs that treat other conditions. This was a small survey, and the questions elicited could only provide a general, descriptive idea of the usual treatment given for prostate cancer. There is a need for large-scale, prospective studies of treatment in prostate cancer." - Anonymous Online Contributor